Subepithelial injection of botulinum toxin A for non-neurogecic overactive bladder - Botulinum toxin injection in non-neurogenic OAB

ational Center for Geriatrics & Gerontology0 sites45 target enrollmentOctober 14, 2008

Overview

No summary available.

Registry

who.int

Start Date

October 14, 2008

End Date

March 1, 2011

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

ational Center for Geriatrics & Gerontology

•1\) The patient has apparent neurogenic diseases causing urinary tract symptoms. 2\) The patient underwent treatment with botulinum toxin A. 3\) The patient underwent the surgery of lower urinary tract within 1 year. 4\) Postvoid residual urine is 100ml or greater. 5\) The patient has apparent lower urinary tract obstruction and/or weak detrusor. 6\) Average voiding volume are 200ml or greater on frequency\-volume chart. 7\) The patient has stress urinary incontinence and/or functional urinary incontinence. 8\) The patient has active urinary tract infection, malignance and/or bladder stone. 9\) The patient is pregnant or breast\-feed, or have possibility of such matter within 1 year. 10\) The patient is diagnosed as having myasthenia gravis, Lambert\-Eaton syndrome, amyotrophic lateral sclerosis. 11\) The patient has disturbance of swallowing and/or respiration. 12\) The patitent has mental and/or cognitive disturbance to conduct the clinical trial. 13\) The patient is judged as being unsuitable for the trial by the researcher.